{"entities":{"Q40459":{"pageid":30827,"ns":120,"title":"Item:Q40459","lastrevid":129809,"modified":"2026-08-13T06:16:37Z","type":"item","id":"Q40459","labels":{"mul":{"language":"mul","value":"6C49.61"},"pt-br":{"language":"pt-br","value":"Transtorno de ansiedade induzido por alucin\u00f3genos"},"en":{"language":"en","value":"Hallucinogen-induced anxiety disorder"}},"descriptions":{"pt-br":{"language":"pt-br","value":"Transtorno de ansiedade induzido por alucin\u00f3genos \u00e9 caracterizado por sintomas ansiosos (p. ex., apreens\u00e3o ou preocupa\u00e7\u00e3o, medo, sintomas fisiol\u00f3gicos de ativa\u00e7\u00e3o auton\u00f4mica excessiva, comportamento de evita\u00e7\u00e3o) que se desenvolvem durante ou logo ap\u00f3s intoxica\u00e7\u00e3o por alucin\u00f3genos. A intensidade ou dura\u00e7\u00e3o dos sintomas \u00e9 consideravelmente maior do que sintomas ansiosos caracter\u00edsticos da intoxica\u00e7\u00e3o por alucin\u00f3genos. A quantidade e dura\u00e7\u00e3o do uso de alucin\u00f3genos devem ser capazes de produzir sintomas de ansiedade. Os sintomas n\u00e3o s\u00e3o mais bem explicados por um transtorno mental prim\u00e1rio (p.ex., transtorno de ansiedade e relacionado ao medo, transtorno depressivo com sintomas ansiosos proeminentes), como pode ser o caso se os sintomas de ansiedade precederam o in\u00edcio do uso de alucin\u00f3genos, se os sintomas persistem por um per\u00edodo de tempo consider\u00e1vel ap\u00f3s a cessa\u00e7\u00e3o do uso de alucin\u00f3genos, ou se h\u00e1 outra evid\u00eancia de um transtorno mental prim\u00e1rio preexistente com sintomas ansiosos (p. ex., hist\u00f3ria de epis\u00f3dios anteriores n\u00e3o associados ao uso de alucin\u00f3genos)."},"en":{"language":"en","value":"Hallucinogen-induced anxiety disorder is characterised by anxiety symptoms (e.g., apprehension or worry, fear, physiological symptoms of excessive autonomic arousal, avoidance behaviour) that develop during or soon after intoxication with hallucinogens. The intensity or duration of the symptoms is substantially in excess of anxiety symptoms that are characteristic of hallucinogen intoxication. The amount and duration of hallucinogen use must be capable of producing anxiety symptoms. The symptoms are not better explained by a primary mental disorder (e.g., an Anxiety and Fear-Related Disorder, a Depressive Disorder with prominent anxiety symptoms), as might be the case if the anxiety symptoms preceded the onset of the hallucinogen use, if the symptoms persist for a substantial period of time after cessation of the hallucinogen use, or if there is other evidence of a pre-existing primary mental disorder with anxiety symptoms (e.g., a history of prior episodes not associated with hallucinogen use)."}},"aliases":{},"claims":{"P68":[{"mainsnak":{"snaktype":"value","property":"P68","hash":"6410d308ee3e62ca8b128ab882b0de22711bead4","datavalue":{"value":"https://id.who.int/icd/entity/1245150953","type":"string"},"datatype":"url"},"type":"statement","id":"Q40459$4F0FF299-4D36-43E0-8AA1-9D1E3613E8E0","rank":"normal"}],"P67":[{"mainsnak":{"snaktype":"value","property":"P67","hash":"d90fe4c7ff3f2d9fbc48efb8f5182c1bd932f1eb","datavalue":{"value":"CID11:6C49.61","type":"string"},"datatype":"string"},"type":"statement","id":"Q40459$88EFDEB3-FE4B-449D-8AB4-E484EC4D4193","rank":"normal"}],"P70":[{"mainsnak":{"snaktype":"value","property":"P70","hash":"61195f23b372d45f3964b866092fdc4e188fdec1","datavalue":{"value":"dki-india-6C49.61","type":"string"},"datatype":"string"},"type":"statement","id":"Q40459$9A25C499-D257-4E47-BCC3-95BEF0FD235A","rank":"normal"}],"P86":[{"mainsnak":{"snaktype":"value","property":"P86","hash":"a96031634b9f5dafddaf781bbba3adea6bb64ef4","datavalue":{"value":"Conclu\u00eddo","type":"string"},"datatype":"string"},"type":"statement","id":"Q40459$54673B8B-68C2-4295-844A-8232C2B67F41","rank":"normal"}],"P78":[{"mainsnak":{"snaktype":"value","property":"P78","hash":"5f9b5be68b7400da549761cf15abfdbc4d1e075b","datavalue":{"value":"https://pauloleads.com.br/cases-publicos/","type":"string"},"datatype":"url"},"type":"statement","id":"Q40459$501F139D-9DA3-4621-87F9-7CC43912A90C","rank":"normal"}],"P80":[{"mainsnak":{"snaktype":"value","property":"P80","hash":"92b8222fcbb75718504f915073a3f43bd4003d18","datavalue":{"value":{"time":"+2026-08-13T00:00:00Z","timezone":0,"before":0,"after":0,"precision":11,"calendarmodel":"http://www.wikidata.org/entity/Q1985727"},"type":"time"},"datatype":"time"},"type":"statement","id":"Q40459$6011FA8A-B519-4CB2-A0CE-5DFD2294BBE9","rank":"normal"}],"P89":[{"mainsnak":{"snaktype":"value","property":"P89","hash":"28cde707e8872b90a67c1eade8d68fdffdefb03f","datavalue":{"value":{"entity-type":"item","numeric-id":16042,"id":"Q16042"},"type":"wikibase-entityid"},"datatype":"wikibase-item"},"type":"statement","id":"Q40459$58D404CA-6787-4AB8-98F8-1D529FB55991","rank":"normal"}]},"sitelinks":{}}}}